Browsing by Author Tinker, Anna V.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2010Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an australia new zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) studyCarter, Jonathan; Friedlander, Michael; Gainford, Mary; Elit, Laurie; Hammond, Ian; Lenhard, Miriam; Nicklin, Jim; Petru, Edgard; Quinn, Michael; Tinker, Anna V.; Central Clinical School: Obstetrics & Gynaecology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreMalignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an australia new zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study, International Journal of Gynecological Cancer, vol.20, 1,pp 75-81
2008Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.deFazio, Anna; Australian Ovarian Cancer Study Group, (AOCSG); Bowtell, David D L; Brown, Robert; Chiew, Yoke-Eng; Etemadmoghadam, Dariush; Fereday, Sian; Fox, Stephen B.; George, Joshy; Gertig, Dorota; Haviv, Izhak; Hung, Jillian A.; Johnson,, Daryl S.; Lade, Stephen; Locandro, Bianca; Tinker, Anna V.; Tothill, Richard W.; Traficante, Nadia; Trivett, Melanie K.; Western Clinical School: Westmead Millennium InstituteNovel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome., Clinical Cancer Research, vol.14, 16, 2008,pp 5198-5208
2017Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinomaBowtell, David; Barker, Holly; et al, Various; Harrell, Maria I.; Ho, Gwo-Yaw; Kondrashova, Olga; Kuiper, Michael J.; Nguyen, Minh; Shield-Artin, Kristy; Teng, Nelson N.H.; Tinker, Anna V.; Westmead Clinical School: MedicineSecondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma, Cancer Discovery, vol.7, 9, 2017,pp 984-998